The enterochromaffin-like (ECL) cells of the oxyntic mucosa (fundus) of the stomach produce, store and secrete histamine, chromogranin A-derived peptides such as pancreastatin, and an unanticipated but as yet unidentified peptide hormone. The cells are stimulated by gastrin and pituitary adenylate cyclase activating peptide and suppressed by somatostatin and galanin. Choline esters and histamine seem to be without effect on ECL cell secretion. The existence of a gastrin-ECL cell axis not only explains how gastrin stimulates acid secretion but also may help to explore the functional significance of the ECL cells with respect to the nature and bioactivity of its peptide hormone. From the results of studies of gastrectomized/fundectomized and gastrin-treated rats, it has been speculated that the anticipated ECL-cell peptide hormone acts on bone metabolism.
INTRODUCTION
This review attempts to summarize what is known of the mechanisms that control the activity of the enterochromaffin-like (ECL)b cells in the rat stomach and describes also current speculations about their functional significance. Morphological aspects of the ECL cells are discussed in another chapter in this volume [1] . The ECL cells are known to produce, store and secrete histamine and chromogranin A (CGA)-derived peptides, such as pancreastatin; in addition, they are suspected to manufacture an as yet unidentified peptide hormone [2, 3] . The secretory products are stored in secretory vesicles, which have a very characteristic ultrastructural appearance [1, [4] [5] [6] [7] . The products appear to be released in parallel in response to stimulation [7, 8] . The functional significance of the ECL cells can be expected to reflect the nature and bioactivity of the secreted products.
ECL CELLS: OPERATIONAL CONTROL
In vivo studies Much information on the mechanisms that control the activity of the ECL cells is already available in the literature from decades of in vivo studies [2, 3] . It is generally accepted that gastrin is a major stimulus for the ECL cells, causing secretory activation as well as hypertrophy/hyperplasia. Secretory activation is manifested in the prompt mobilization of histamine and pancreastatin and followed by activation of the histamine-forming enzyme histidine decarboxylase (HDC). If the gastrin stimulus is sustained for a long period of time the ECL cells will respond with hypertrophy and general, diffuse hyperplasia, and ultimately with dysplasia (focal hyperplasia and micronodules) and neoplasia (frank tumors) [9] .
Although it seems to be generally accepted that the ECL cells operate under vagal control the evidence for this view is not overwhelming. Gastrin to interact in an intricate manner in regulating various activities in the oxyntic mucosa (e.g., ECL cell activation, parietal cell activation), and it is difficult to define the precise contribution of each individual stimulus on each individual target. From published reports it appears that vagally denervated ECL cells respond poorly to the trophic action of gastrin [10] [11] [12] . It appears to be generally accepted that the vagus controls the ECL cells and that acetylcholine is the neurotransmitter involved. In fact, however, the vagal control of the ECL cells (and of all other epithelial cells in the oxyntic mucosa) is mediated by enteric neurons (probably those in the myenteric plexus) [13] , and the nature and identity of the relevant transmitters are unknown.
The activity of the ECL cells can be suppressed by exogenously administered somatostatin [14] and histamine [15, 16] . Somatostatin occurs in paracrine cells in the oxyntic mucosa [14, 17] and is thought to modulate the activity of the ECL cells by way of direct contact or per diffusionem. In the past, exogenous histamine has been found to be quite effective in suppressing the HDC activity of the ECL cells [15] . In fact, histamine was proposed to suppress the activity of the ECL cell by way of auto feedback inhibition; the receptor involved was tentatively identified as a histamine H2-receptor [16] . However, the design of these experiments was such that indirect effects of histamine could not be excluded. Each agent was tested on at least four separate isolated cell preparations, except in the case of CGRP, NPY, PYY, PP, PACAP, choline esters and histamine. The latter agents were screened at least 10 times. Peptides were tested at a concentration 10-7 M. All other agents were screened at 10-4 M concentration. Suppression was studied with cells stimulated with EC80 gastrin. ++++, potent and powerful; +++, strong; ++, moderate; +, weak; -, no effect. EC50, concentration of peptide that elicits 50% of maximum effect.
In vitro studies
The fairly recent development of a method for the preparation of isolated, near-pure ECL cells by Prinz et al. [18, 19] will make it possible to demonstrate receptors and binding sites on the ECL cells directly and to examine in detail the signal transduction mechanisms that are activated by the different stimuli. We have accumulated data from studies of more than 200 preparations of isolated ECL cells with a reproducible yield of 2-3 x 106 ECL cells from five rat stomachs; the ECL cells constitute 80-90 percent of the cells in the final preparation [8] . A number of regulatory peptides and neurotransmitters were tested for their ability to affect secretion from the ECL cells. A fairly limited number of the agents tested were found to be active (Table 1) . Briefly, gastrin causes a parallel release of histamine and pancreastatin, and also the neuropeptides pituitary adenylate cyclase activating peptide (PACAP) and vasoactive intestinal peptide (VIP) were able to stimulate secretion. PACAP was more potent than gastrin, while VIP seemed to be less potent (Table  2) . Of the regulatory peptides tested not only somatostatin but also galanin were able to suppress gastrin-evoked (and PACAP-evoked) secretion (Table 2) . Choline esters and the amino acid transmitters tested were inactive, while catecholamines and 5-hydroxytryptamine were moderately active. Our results differ from previously published reports in several instances. Thus, we failed to observe an inhibiting effect of histamine. We also failed to find a stimulating effect of choline esters. Since acetylcholine was inactive, it is unlikely that the vagal control of the ECL cells is cholinergic. Instead, the nervous control may be exercised by enteric neurons that use PACAP (or possibly VIP) as the excitatory transmitter and galanin as the inhibitory transmitter. Interestingly, the oxyntic mucosa is richly supplied with nerve fibers that contain PACAP and/or VIP [13, [20] [21] [22] . Also galanin occurs in nerve fibers in the oxyntic mucosa [23] . We conclude from our data that not only gastrin but also PACAP is a powerful excitant of the ECL cells, that not only somatostatin but also galanin can suppress secretion, that muscarinic receptor agonists fail to evoke secretion, and that histamine (and pancreastatin) does not evoke auto feedback inhibition [8] . [2, 3] . The relationship between gastrin and the ECL cells is so close that we have proposed the term gastrin-ECL cell axis. The biological significance of the ECL cells is linked with the actions of locally released histamine and the systemic actions of the anticipated ECL-cell peptide hormone. ECL-cell histamine is mobilized by gastrin to stimulate the parietal cells [24, 25] and it appears to be generally accepted by now that the acid-stimulating effect of gastrin is mediated by ECL-cell histamine. The evidence for this view is summarized in another chapter of this book [26] . It may be pointed out here that ECL-cell histamine does not seem to mediate vagus-stimulated acid secretion [25] .
It is not unusual to see the ECL cells dismissed as representing merely the local source of gastric histamine necessary for the activation of the parietal cells. In fact, however, there is compelling evidence that the ECL cells produce not only histamine but also a peptide hormone. The concomitant formation of an amine and a regulatory peptide is a feature shared with a great many different peptide hormone-producing cell populations [27] . Admittedly, the arguments in favor of the view that the ECL cells are the source of a peptide hormone are indirect. First, the ECL cells share the properties of all other peptide hormone-producing endocrine cells in the body (Table 3) . Recently, they were found to be supplied with the full range of exocytotic proteins associated with neurons and endocrine cells [28] . In addition, observations documented in the literature make it possible to speculate that the ECL cells are engaged in specific functions not related to histamine (see below).
FUNCTIONAL SIGNIFICANCE OF THE ECL CELLS
Circulating pancreastatin-a marker ofECL cell activity and number
The ECL cells constitute one of the largest endocrine cell populations in the body. They are rich in CGA-derived peptides, such as pancreastatin [7, 29, 30] . The ECL cells contain about 25 percent of the body's total content of pancreastatin and account for 75 percent of the circulating pancreastatin [31] . Furthermore, at least 90 percent of circulating pancreastatin in hypergastrinemic rats (omeprazole treatment) derive from the ECL cells [32] . From these data it can be surmised that the ECL cell population represents a quantitatively prominent endocrine organ. CGA and the CGA-derived peptides are generally thought to play a role in the packaging, processing and storage of the actual secretory products rather than being messenger compounds in their own right [33] . It is possible, [34, 35] . It was generally assumed at the time that the osteopathy reflected nutritional deficiency. Since then numerous observations both in the clinical setting and in experimental animals have confirmed the importance of the stomach for skeletal health.
As expected, gastrectomy causes the development of osteopathy in the rat [36] [37] [38] [39] [40] . This was manifested in all bones examined, most dramatically in the calvaria [37] . Also, trabecules were lost to a great extent [36] . The effect was near-maximal within 8-12 weeks (Figure 1 ). There are several possible explanations for the gastrectomy-evoked osteopathy. First, general nutritional deficiency may be responsible. However, the food intake appeared normal and the curve illustrating the body weight development was not much affected by the surgery. Hence, it is unlikely that a general nutritional deficiency accounts for the gastrectomy-evoked bone loss. Also, calcium supplementation by the peroral or systemic route failed to prevent the gastrectomy-evoked osteopathy [36, 37] (Figure 2 ). At present, we have no evidence that vitamin D deficiency contributes to the gastrectomyevoked osteopathy [41] . Circulating concentrations of Ca+2, PTH and calcitonin were unaffected by gastrectomy (HAkanson et al., to be published). Hence it is unlikely that hyperparathyroidism is responsible for the gastrectomy-evoked bone loss. Lack of gastric acid, as after treatment with the proton pump inhibitor omeprazole, did not induce osteopathy [36] . It appears therefore that the gastrectomy-evoked bone loss is a consequence of the loss of the stomach per se and that the stomach plays an as yet unidentified role in controlling bone status. In another series of experiments we tried to establish whether defined parts of the stomach were as important to bone metabolism as was the whole stomach [39] . Removal of the acid-producing part of the stomach (fundectomy) resulted in the same degree of osteopathy as did gastrectomy, whereas antrectomy had only little effect. We conclude that while fundectomy completely reproduces the effects of gastrectomy, antrectomy has little effect. We speculate therefore that the bone loss observed after gastrectomy reflects the loss of the oxyntic mucosa and of a circulating hormone originating in one of the endocrine cell populations in this location.
Schulak and Kaplan [42, 43] and Kaplan et al. [44] reported that gastrin evokes transient hypocalcemia in the rat. This effect was unaffected by thyroparathyroidectomy but abolished by gastrectomy or fundectomy. We were able to confirm these observations with respect not only to exogenous but also to endogenous gastrin [45] [46] [47] . In addition, we demonstrated that gastrin-free extracts of the oxyntic mucosa mimicked the effect of gastrin on blood calcium. The gastrin-induced hypocalcemia reflected the stimulated uptake of 45Ca2+ into bone. We suggest that gastrin causes hypocalcemia by releasing a blood calcium-lowering hormone from the acid-producing part of the stomach and speculated that the oxyntic mucosa contains a hormone (gastrocalcin), which is released in response to gastrin (which in turn is released in response to food intake) [48] . The ECL cells are likely candidates for such a hormone because they operate under the control of gastrin.
If the ECL cells secrete a calciotropic hormone it is to be expected that they should respond to perturbations in the concentration of blood Ca2+. While changes in the blood Ca2+ concentration induced the expected changes in the circulating concentrations of calcitonin and PTH, the ECL cells failed to respond [49] . We conclude that the ECL cells do not secrete a calciotrophic hormone. It cannot be excluded, however, that they produce a hormone with a primary action on bone rather than on Ca2+
